Apogenix (Germany) has been granted €3M for a personalized medicine to treat glioblastoma. It will also use this funding to develop a companion diagnostic test using a specific cancer biomarker, which other German biotechs are also attempting to do…
This Heidelberg based-biotech (which we visited on our Labiotech tour of South Germany) is focused on the development of protein Immuno-Oncology therapeutics to treat malignancies, such as glioblastoma, a type of rare brain cancer.
The CancerMark project was initiated in February 2016 by the German Federal Ministry of Education and Research. With a funding period of three years, the goal of the CancerMark project is to confirm the efficacy of Apogenix’s immuno-oncology candidate (APG101).
In an addition, the clinical trial hopes to validate a companion diagnostic test to analyze the biomarker associated with the CD95 ligand, a cell death mediator implicated in cancer.
This is because it was found that the Glioblastoma patients which expressed a certain biomarker associated with the CD95 ligand experienced the greatest benefit from treatment with APG101.